Compounds > ci 943
Page last updated: 2024-12-08

ci 943

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CI 943: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID146009
CHEMBL ID143865
SCHEMBL ID10918513
MeSH IDM0169948

Synonyms (21)

Synonym
ci-943
1h-imidazo(1,2-c)pyrazolo(3,4-e)pyrimidine, 8-ethyl-7,8-dihydro-1,3,5-trimethyl-
1h-imidazo(1,2-c)pyrazolo(3,4-e)pyrimidine, 7,8-dihydro-8-ethyl-1,3,5-trimethyl-
ci 943
7,8-dihydro-8-ethyl-1,3,5-trimethyl-1h-imidazo(1,2-c)pyrazolo(3,4-e)pyrimidine
CHEMBL143865 ,
7-ethyl-1,3,5-trimethyl-6,7-dihydro-1h-1,2,4,5a,8-pentaaza-as-indacene
bdbm50019968
wuy06k900n ,
89239-35-0
unii-wuy06k900n
SCHEMBL10918513
8-ethyl-1,3,5-trimethyl-7,8-dihydro-1h-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidine
ci-943, (+/-)-
8-ethyl-7,8-dihydro-1,3,5-trimethyl-1h-imidazo-(1,2-c)pyrazolo(3,4-e)pyrimidine
HY-100161
CS-0018157
DTXSID80880064
(+/-)-ci 943
11-ethyl-3,5,8-trimethyl-3,4,7,9,12-pentazatricyclo[7.3.0.02,6]dodeca-1(12),2(6),4,7-tetraene
AKOS040741549

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Treatment-related effects were evident for each behavioral parameter; they occurred at parentally toxic and nontoxic doses and in the absence of detrimental effects on offspring growth and development."( Developmental neurotoxicity of CI-943: a novel antipsychotic.
Anderson, JA; Henck, JW; Petrere, JA, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID126467Inhibition of Sidman avoidance in squirrel monkeys after the compound administered through perorally1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID31387Displacement of [3H]CHA (N6-Cyclohexyl adenosine) from adenosine A1 receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID61382Displacement of [3H]haloperidol from Dopamine receptor D2 in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID130897Inhibition of locomotor activity in mouse after intraperitoneal administration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID40806Displacement of [3H]flunitrazepam from GABA-A benzodiazepine receptor of rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID177879Inhibition of Sidman avoidance in rats after peroral administration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID141420Displacement of [3H]quinuclidinyl benzilate(QNB) from Muscarinic acetylcholine receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID41351Displacement of [3H]DHA (Dihydroalprenolol) from beta-2 adrenergic receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID36663Displacement of [3H]clonidine from alpha-2 adrenergic receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID36590Displacement of [3H]WB-4101 from alpha-1 adrenergic receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID95590Displacement of [3H]nitrendipine from L-type [Ca2+] channel of rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID178237Inhibition of self-stimulation in rats after the compound administered through perorally1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID61017Displacement of [3H]cis-flupenthixol from Dopamine receptor D1 in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID178242Inhibition of shelf-jump avoidance in rats after peroral administration.1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID178061Inhibition of locomotion in rats after the compound administered through perorally1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID5057Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID200921Displacement of [3H]5-HT from serotonin-1 neurotransmitter receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID40398Displacement of [3H]DHA (Dihydroalprenolol) from beta-1 adrenergic receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID130893Inhibition of induction of ataxia in mouse after intraperitoneal administration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (62.50)18.7374
1990's2 (25.00)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.22 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		2.6630aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
spiperone
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.		1.9710aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
thioridazine
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.		1.9710phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
dextroamphetamine
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.		1.97101-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		2.3820aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
neurotensin
neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91		3.4820peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		2.3720benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		02.1310
Impotence
[description not available]		02.1310
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		02.1310
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.1310
Erectile Dysfunction
The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.		02.1310